189 related articles for article (PubMed ID: 18060083)
21. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness.
Yun O; Priotto G; Tong J; Flevaud L; Chappuis F
PLoS Negl Trop Dis; 2010 May; 4(5):e720. PubMed ID: 20520803
[No Abstract] [Full Text] [Related]
22. African sleeping sickness.
Hedley L; Fink D; Sparkes D; Chiodini PL
Br J Hosp Med (Lond); 2016 Oct; 77(10):C157-C160. PubMed ID: 27723399
[No Abstract] [Full Text] [Related]
23. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.
Chappuis F; Udayraj N; Stietenroth K; Meussen A; Bovier PA
Clin Infect Dis; 2005 Sep; 41(5):748-51. PubMed ID: 16080099
[TBL] [Abstract][Full Text] [Related]
24. Production of sleeping-sickness treatment.
Pécoul B; Gastellu M
Lancet; 1999 Sep; 354(9182):955-6. PubMed ID: 10489988
[No Abstract] [Full Text] [Related]
25. Killer coma: the evolving story of sleeping sickness treatment.
Lancet; 2010 Jan; 375(9709):93. PubMed ID: 20109869
[No Abstract] [Full Text] [Related]
26. Drug resistance in human African trypanosomiasis.
Barrett MP; Vincent IM; Burchmore RJ; Kazibwe AJ; Matovu E
Future Microbiol; 2011 Sep; 6(9):1037-47. PubMed ID: 21958143
[TBL] [Abstract][Full Text] [Related]
27. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial.
Pépin J; Khonde N; Maiso F; Doua F; Jaffar S; Ngampo S; Mpia B; Mbulamberi D; Kuzoe F
Bull World Health Organ; 2000; 78(11):1284-95. PubMed ID: 11143188
[TBL] [Abstract][Full Text] [Related]
28. Treatment of human African trypanosomiasis--present situation and needs for research and development.
Legros D; Ollivier G; Gastellu-Etchegorry M; Paquet C; Burri C; Jannin J; Büscher P
Lancet Infect Dis; 2002 Jul; 2(7):437-40. PubMed ID: 12127356
[TBL] [Abstract][Full Text] [Related]
29. [Agents for the treatment of African sleeping sickness. Those developed in the last century].
Schlitzer M
Pharm Unserer Zeit; 2009; 38(6):552-8. PubMed ID: 19862727
[No Abstract] [Full Text] [Related]
30. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.
Jansson-Löfmark R; Na-Bangchang K; Björkman S; Doua F; Ashton M
Antimicrob Agents Chemother; 2015 Feb; 59(2):1299-307. PubMed ID: 25512417
[TBL] [Abstract][Full Text] [Related]
31. Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.
Dauchy FA; Bonhivers M; Landrein N; Dacheux D; Courtois P; Lauruol F; Daulouède S; Vincendeau P; Robinson DR
PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005125. PubMed ID: 27855164
[TBL] [Abstract][Full Text] [Related]
32. A seven days course of eflornithine for relapsing Trypanosoma brucei gambiense sleeping sickness.
Khonde N; Pépin J; Mpia B
Trans R Soc Trop Med Hyg; 1997; 91(2):212-3. PubMed ID: 9196773
[TBL] [Abstract][Full Text] [Related]
33. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda.
Priotto G; Fogg C; Balasegaram M; Erphas O; Louga A; Checchi F; Ghabri S; Piola P
PLoS Clin Trials; 2006 Dec; 1(8):e39. PubMed ID: 17160135
[TBL] [Abstract][Full Text] [Related]
34. The evolving spectrum of human African trypanosomiasis.
Kennedy PGE
QJM; 2024 Jun; 117(6):391-395. PubMed ID: 38065835
[TBL] [Abstract][Full Text] [Related]
35. The rise and fall of sleeping sickness.
Barrett MP
Lancet; 2006 Apr; 367(9520):1377-8. PubMed ID: 16650633
[No Abstract] [Full Text] [Related]
36. Eflornithine. A new drug in the treatment of sleeping sickness.
Van Bogaert I; Haemers A
Pharm Weekbl Sci; 1989 Jun; 11(3):69-75. PubMed ID: 2505225
[TBL] [Abstract][Full Text] [Related]
37. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study.
Priotto G; Pinoges L; Fursa IB; Burke B; Nicolay N; Grillet G; Hewison C; Balasegaram M
BMJ; 2008 Mar; 336(7646):705-8. PubMed ID: 18321960
[TBL] [Abstract][Full Text] [Related]
38. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.
Matovu E; Enyaru JC; Legros D; Schmid C; Seebeck T; Kaminsky R
Trop Med Int Health; 2001 May; 6(5):407-11. PubMed ID: 11348535
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes.
Balasegaram M; Young H; Chappuis F; Priotto G; Raguenaud ME; Checchi F
Trans R Soc Trop Med Hyg; 2009 Mar; 103(3):280-90. PubMed ID: 18947846
[TBL] [Abstract][Full Text] [Related]
40. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
Sokolova AY; Wyllie S; Patterson S; Oza SL; Read KD; Fairlamb AH
Antimicrob Agents Chemother; 2010 Jul; 54(7):2893-900. PubMed ID: 20439607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
